Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody

BIOLOGICAL2 trials

Sponsors

Baxalta now part of Shire

Conditions

Malignant Solid TumorsMetastatic Adenocarcinoma of the Colon or RectumSystemic Lupus Erythematosus

Phase 1

Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis

TerminatedNCT01541670

Baxalta now part of ShireSystemic Lupus Erythematosus

Start: 2011-11-28End: 2012-12-31Updated: 2021-05-05

Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors

CompletedNCT01765790

Baxalta now part of ShireMalignant Solid Tumors, Metastatic Adenocarcinoma of the Colon or Rectum

Start: 2012-06-14End: 2016-07-28Updated: 2021-05-05

Related Papers

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

British Journal of Clinical Pharmacology2020-03-2474 citations

Abstract CT046: First-in-human phase 1 study assessing imalumab (BAX69), an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors

Cancer Research2016-07-151 citations

Abstract A153: Imalumab, a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody penetrates tumor tissues and shows antitumor activity in patients

Molecular Cancer Therapeutics2015-12-013 citations

Abstract 2475: A novel class of fully human monoclonal anti-oxMIF antibodies penetrates metastases and accumulates in tumor tissue

Cancer Research2015-08-01

Abstract 3385: Cancerous tissue can be identified by the presence of oxMIF, the oxidized form of macrophage migration inhibitory factor

Cancer Research2015-08-01

First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors.

Journal of Clinical Oncology2015-05-209 citations

Development of a phase Ib/IIa proof-of-concept study of imalumab (BAX69), a first-in-class anti-macrophage migration inhibitory factor (MIF) antibody, as the 3<sup>rd</sup> or 4<sup>th</sup> line treatment in metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2015-05-205 citations

Abstract 4841: Oxidized macrophage migration inhibitory factor (oxMIF) expressed by tumor stroma and tumor cells, contributes to tumor growth

Cancer Research2014-10-011 citations

Abstract 2654: Human antibodies specific for oxidized macrophage migration inhibitory factor (oxMIF) synergize with chemotherapeutic agents in animal models of cancer

Cancer Research2014-10-01

Abstract A181: Oxidized macrophage migration inhibitory factor (oxMIF) is a previously unrecognized, disease-related isoform of MIF and a potential new drug target in cancer.

Molecular Cancer Therapeutics2013-11-01